Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01667796 · ClinicalTrials.gov registry record · NA
Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health
A NA study of Multiple Sclerosis (Relapsing Remitting), sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 57
- Enrollment target
- 2
- Study locations
NCT01667796: Completed NA study of Multiple Sclerosis (Relapsing Remitting), sponsored by Johns Hopkins University.
NCT01667796 is a NA study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Johns Hopkins University. The registered enrollment target is 57 participants, below the 561-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01667796, a NA study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a pilot study of oral vitamin D supplementation to determine if patients with Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin D levels. The investigators will also assess whether the immunologic or relevant gene expression response to oral vitamin D supplementation differs in patients with MS and healthy controls.
Primary Outcome
Generalized estimating equations (GEE) with an autoregressive with lag one correlation matrix were used to compare the serially-measured serum 25(OH)D levels between MS patients and Healthy Controls (HCs) to take into account repeated measures and within-subject correlations.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Vitamin D3
Study Locations (2)
California
- University of California, San Francisco - San Francisco
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-03 |
| Phase | NA |
What the finished NCT01667796 record still lists
NCT01667796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 561-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 1 intervention - of which Vitamin D3 is the first listed.
NCT01667796 reports a single indexed study location in California, Maryland.
Frequently Asked Questions
What is clinical trial NCT01667796 about?
NCT01667796 is a clinical study titled "Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health". This is a pilot study of oral vitamin D supplementation to determine if patients with Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin D levels. The investigators will also assess whether the immunologic or relevant gene expression response to oral...
What is the current status of trial NCT01667796?
This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2010-11. Estimated completion is 2014-03.
What conditions does trial NCT01667796 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
What interventions are being tested in trial NCT01667796?
The interventions under investigation include: Vitamin D3 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01667796?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01667796 being conducted?
This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01667796's enrollment target sits among peer trials
57 20th of 29 higher than 10 of 29 other Multiple Sclerosis (Relapsing Remitting) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis (Relapsing Remitting) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
RECRUITING · NA
-
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
RECRUITING · NA
-
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
RECRUITING · NA
-
The Synergistic Effects of AIH and FES in Persons With MS
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia